BHVN — Biohaven Ltd.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1935979 ·
Last close
$10.07
Market Cap
$1.52B
52W High
$12.10
52W Low
$8.03
ADV30
1,904,686
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -130,428,000 | -130,532,000 | 466,406,000 | 273,074,000 | 336,906,000 |
| Dec 2025 | 0 | — | -142,734,000 | -145,555,000 | 451,447,000 | 229,957,000 | 399,375,000 |
| Sep 2025 | 0 | — | -169,382,000 | -173,443,000 | 409,123,000 | 184,847,000 | 426,283,000 |
| Jun 2025 | 0 | — | -211,701,000 | -198,147,000 | 550,415,000 | 165,797,000 | 415,828,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-594,232,000
Investing CF
$150,894,000
Financing CF
$617,764,000
CapEx
$-715,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.67
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,215,068,000
Inventory
—
Receivables
$2,597,000
ST Investments
$74,743,000
EBIT TTM
$-654,245,000
Pretax Income TTM
$-646,572,000
Interest Exp TTM
—
Analysts
17
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -745,378,000 | -738,822,000 | 451,447,000 | 399,375,000 | — | -609,438,000 |
| Dec 2024 | 0 | -885,111,000 | -846,422,000 | 615,107,000 | 191,671,000 | — | -582,453,000 |
| Dec 2023 | 0 | -436,051,000 | -408,168,000 | 513,212,000 | 85,237,000 | — | -331,725,000 |
| Dec 2022 | 0 | -567,932,000 | -570,279,000 | 661,783,000 | 123,012,000 | — | -297,689,000 |
TTM Snapshot
Revenues TTM
$443,853,000
NetIncome TTM
$-386,096,000
OpCashFlow TTM
$0
Assets (Latest)
$615,107,000
Forward EPS
$-1.95
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PGEN | PRECIGEN, INC. | $1.51B | $4.24 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $1.52B | $13.68 | — |
| MBX | MBX Biosciences, Inc. | $1.51B | $31.75 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $1.51B | $8.12 | — |
| PRGO | PERRIGO Co plc | $1.49B | $10.80 | — |
News headlines (Yahoo Finance, 1h cache)
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
2026-05-26 11:30 · Yahoo
Biohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf Registration - What's Changed
2026-05-06 23:15 · Yahoo
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
2026-05-05 16:00 · Yahoo
A Look At Biohaven (BHVN) Valuation After Narrower Q1 Loss And New Pivotal Trial And Funding Plans
2026-05-05 04:35 · Yahoo
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
2026-05-04 20:02 · Yahoo
KCNQ2 Developmental and Epileptic Encephalopathy Market Research Report 2025-2035, Competitive Analysis of Biohaven, Xenon Pharma, Lundbeck, Praxis Precision Medicines, NeuShen Therapeutics
2026-04-28 08:06 · Yahoo
Moderate Buy Rating Seen For Biohaven Ltd. (BHVN)
2026-04-22 14:18 · Yahoo
Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating
2026-04-20 00:11 · Yahoo
Why Biohaven Stock Crushed it on Monday
2026-04-13 22:01 · Yahoo
Here is why Biohaven (BHVN) is Among the Top Healthcare Stocks Insiders Are Buying
2026-04-12 21:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.